Amneal Pharmaceuticals Inc Stock Price, News & Analysis

Amneal Pharmaceuticals (NYSE: AMRX) recently announced FDA approval for FYLNETRA (pegfilgrastim-pbbk), a biosimilar to Neulasta®, marking its third biosimilar approval in 2022. Developed in partnership with Kashiv Biosciences, FYLNETRA is intended to treat neutropenia in chemotherapy patients. This approval further solidifies Amneal's position in the $28 billion U.S. biosimilars market, where annual pegfilgrastim sales reached $3.1 billion. The company plans to launch FYLNETRA along with its other biosimilars later this year.

Amneal Pharmaceuticals, Inc. (NYSE: AMRX) announced participation in the 2022 Jefferies Healthcare Conference on June 8, 2022, in New York City. Co-CEO Chirag Patel and CFO Tasos Konidaris will represent the company, with Patel hosting a presentation at 8:00 AM ET. A live webcast of the presentation will be available on the Investor Relations section of their website, followed by a replay accessible for 90 days. Amneal specializes in generic and specialty pharmaceuticals, focusing on essential medicines and a diverse product portfolio.

Amneal Pharmaceuticals (NYSE: AMRX) will participate in several investor conferences, including the RBC Healthcare Conference on May 17, 2022, and the UBS Healthcare Conference on May 25, 2022, both in New York City. Additionally, the company will feature in the Barclays CEO Call Series on May 27, 2022, at 10:00 AM Eastern Time. As a fully-integrated essential medicines company, Amneal specializes in generic and specialty pharmaceuticals with a diverse portfolio of over 250 products. For more information, visit www.amneal.com.

Amneal Pharmaceuticals (AMRX) reported Q1 2022 net revenue of $498 million, a 1% increase from Q1 2021. The company faced a net loss of $2 million compared to a net income of $7 million last year. Adjusted EBITDA was $100 million, down 13% year-over-year, and adjusted diluted EPS was $0.12, down from $0.17. Despite challenges, Amneal maintains its 2022 financial outlook with net revenue guidance of $2.15 billion - $2.25 billion and adjusted EBITDA of $540 million - $560 million.

Amneal Pharmaceuticals (NYSE: AMRX) has received FDA approval for ALYMSYS®, a biosimilar referencing Avastin®, marking the second of three oncology biosimilar approvals expected in 2022. Developed in partnership with mAbxience, ALYMSYS® addresses a $2.6 billion market, with $1.6 billion from biosimilars alone. This product targets various cancers, enhancing Amneal's position in the growing U.S. biosimilars market, estimated at $28 billion. The company's strategic focus aims to deliver affordable medicines to patients while continuing to innovate within the pharmaceutical landscape.

Amneal Pharmaceuticals, Inc. (NYSE: AMRX) will announce its first quarter 2022 financial results on May 4, 2022, before the market opens. A conference call and live webcast with investors will occur at 8:30 a.m. Eastern Time the same day. Investors can access the financial results and the webcast on the company’s Investor Relations website. For those wishing to join the call, U.S. participants can dial (844) 200-6205 and international callers can use (929) 526-1599, with access code 874223.

Amneal Pharmaceuticals (NYSE: AMRX) has announced the presentation of topline results from its pivotal Phase 3 RISE-PD trial for IPX-203, a novel CD/LD formulation for Parkinson's disease, at the American Academy of Neurology Annual Meeting from April 2-7, 2022, in Seattle, WA. The trial demonstrated significant improvement in "Good On" time per dose, indicating potential benefits in symptom control. A New Drug Application is planned for submission in Q2 2022. The study involved 506 patients across 105 sites in the U.S. and Europe, showcasing Amneal's commitment to advancing Parkinson's treatments.

Amneal Pharmaceuticals (NYSE: AMRX) has secured a sub-license from the Medicines Patent Pool (MPP) to manufacture and commercialize a generic version of nirmatrelvir, co-packaged with ritonavir, in 95 low- and middle-income countries. This oral protease inhibitor, marketed as PAXLOVID^TM by Pfizer, has shown an 89% reduction in COVID-19-related hospitalizations. Amneal aims to produce nirmatrelvir in India and utilize its FDA-approved generic ritonavir from both India and the U.S., potentially delivering hundreds of millions of doses to impacted populations.

Amneal Pharmaceuticals (NYSE: AMRX) reported Q4 2021 net revenue of $537 million, a 5% increase from Q4 2020, despite a GAAP net loss of $6 million. Full year net revenue reached $2.1 billion, up 5% year-over-year, with a GAAP net income of $11 million. Adjusted figures showed significant growth, including Adjusted Net Income of $258 million and Adjusted EBITDA of $538 million for 2021. For 2022, the company expects net revenue between $2.15 billion and $2.25 billion and adjusted EBITDA of $540 million to $560 million.